Skip to main content
Shenzhen Neptunus Interlong Bio-Technique Company Limited logo

Shenzhen Neptunus Interlong Bio-Technique Company Limited — Investor Relations & Filings

Ticker · 8329 HKEX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 8329

About Shenzhen Neptunus Interlong Bio-Technique Company Limited

http://www.interlong.com

Shenzhen Neptunus Interlong Bio-Technique Company Limited is engaged in the comprehensive lifecycle of pharmaceutical products and medical devices, encompassing research and development, manufacturing, and sales. The company utilizes modern biotechnology and advanced drug formulation techniques as its primary innovation platform. Its core business focuses on developing cytokine protein therapeutic drugs and preventive biological products (biologics). The product portfolio addresses diverse therapeutic needs, including oncology, cardiovascular, respiratory, digestive, and mental health systems. The company emphasizes building core competitiveness through proprietary intellectual property and specialized marketing capabilities, aiming to secure a leading position in its primary markets while actively pursuing international strategic expansion.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings
2026-05-04 English
2025 Environmental, Social and Governance Report
Environmental & Social Information Classification · 1% confidence The document is titled “Environmental, Social and Governance Report 2025” of Shenzhen Neptunus Interlong Bio-technique Company Limited, contains full ESG disclosures including materiality assessment, environmental and social KPIs, governance, stakeholder communication, and references to HKEx ESG Reporting Code. It is a standalone ESG report and fits the Environmental & Social Information category.
2026-04-24 English
2025 Annual Report
Regulatory Filings
2026-04-24 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2026
Regulatory Filings Classification · 1% confidence The document is a routine monthly return (Form FF301) submitted to the Hong Kong Stock Exchange under Chapter 19B Listing Rules, detailing movements in authorised/issued share capital and confirmations of public float. It is not an earnings announcement, management discussion, or AGM material, nor is it an announcement of a forthcoming report. It is a direct regulatory filing reporting share capital movements. No other category precisely matches a monthly listing return, so it falls under General Regulatory Filings (RNS).
2026-04-01 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025” and comprises audited consolidated financial statements (profit or loss, financial position, changes in equity) and detailed notes for the year. It is not an AGM materials pack, nor a board or management change notice, nor a proxy or voting announcement. It isn’t the full annual report (10-K) with directors’ report, governance section and MD&A – rather it is the initial public release of the year‐end results. This matches our definition of an Earnings Release (ER), albeit for the annual period rather than a quarter. Therefore, the correct classification is ER. FY 2025
2026-03-25 English
INSIDE INFORMATION ANNOUNCEMENT SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PROFIT WARNING
Regulatory Filings Classification · 1% confidence The document is an "Inside Information Announcement" under HKEX rules providing a supplemental profit warning rather than full financial results, management discussion, or an AGM/EGM event. It contains material regulatory disclosure of expected net loss but does not present complete financial statements (so not an Annual report or interim report), does not solicit votes or present proxy materials, does not announce dividends, M&A, or management changes. Thus, it is a general regulatory announcement and falls under the fallback category: Regulatory Filings (RNS).
2026-03-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.